NCT Number: NCT00225485
Study Evaluating Effexor XR in Elderly Patients With Major Depression.
Phase III study evaluating Effexor XR in elderly patients with major depression.
Looking for future studies?
Notify MeKey information
Conditions
Age range
65 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Ichikawa, Chiba, Japan
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients diagnosed with major depression based on DSM-IV-TR
- Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" of HAM-D at baseline
Exclusion criteria
- Patients with schizophrenia or any other psychotic disorder
- Patients with history or presence of bipolar disorder
Treatment and study plan
Primary outcomes
-
Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy
Secondary outcomes
-
Difference of total score of HAM-D17 between baseline and final-on-therapy
-
Remission rate of HAM-D17 at the final-on-therapy
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Phase III Study of Effexor XR for the Treatment of Elderly Patients With Depression
Important dates
- Study start
- 2003
- First posted
- Sep 23, 2005
- Registry last updated
- May 28, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment
NCT06139016
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial DetailsEffectiveness of Integrated Network for Student Psychosocial Intervention, Resilience, and Education (INSPIRE) on Mental Health Outcomes Among Indonesian Adolescents in Bandung
NCT06942637
Adolescents, Anxiety
Bandung, West Java, Indonesia
View Trial DetailsRapid Antidepressant Improvement Secondary to Excitatory Brain Responses
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsMicrocurrent Neurofeedback as an Adjunct to Standard Care for Substance Use Disorders
NCT07737652
Anxiety, Anxiety Disorders
Tuscaloosa, Alabama, United States
View Trial Details